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ABSTRACT 
Pain is one of the most common reasons for seeking healthcare, with approximately forty 
percent of those suffering from chronic pain having joint pain. Osteoarthritis is the most 
common cause of joint pain, but currently there are few treatments available. The search for 
new, effective pain treatment has been mostly unsuccessful, in spite of the discovery of 
mechanisms that are involved in the transmission of nociceptive signals from the periphery to 
the central nervous system where pain is experienced. This work focuses on the evaluation of 
rodent joint pain models, the behavioural manifestations of the injuries, and the possibility to 
detect treatment effects in these models.  
Three models have been evaluated in rats; intra-articular injection of carrageenan, Freund´s 
complete adjuvant (CFA), and monoiodoacetate (MIA) into one hind leg. In mice, two 
models have been evaluated; intra-articular injection of CFA, and the surgical model of 
anterior cruciate ligament transection (ACLT). Carrageenan injection resulted in an acute, 
robust inflammation, CFA injection caused a more long-lasting strong joint inflammation, 
and MIA injection resulted in an almost complete loss of joint cartilage after a few weeks. 
The model more resembling osteoarthritis was the surgical model, ACLT, which gave severe 
cartilage degeneration, osteophytes, and pathophysiological changes in synovia and 
ligaments. 
Gait and weight bearing during locomotion have been tested in all models. The degree of 
weight bearing reduction in the affected limb was largest in the CFA- and carrageenan-
induced model, followed by the MIA model and least effect was seen in the ACLT surgical 
model. Thus the ACLT model was not possible to use for pharmacological evaluation of 
drugs, whereas carrageenan- and CFA-induced monoarthritis resulted in a big enough 
difference between animals with monoarthritis and those without, to test drugs commonly 
used for pain as well as those under investigation for effects on pain. 
Conventional pain relieving drugs such as non-stereoidal anti-inflammatory drugs (NSAIDs) 
and opioids were able to normalize effects on weight bearing caused by both the carrageenan- 
and the CFA-induced monoarthritis, as were treatments based on inhibiting the NGF-TrkA 
pathway; an anti-NGF antibody and two pan-Trk compounds. However, an antagonist of the 
TRPV1 receptor lacked effect. 
We also investigated mice with a mutation in the R100 NGFß gene (hR100E), in comparison 
with mice possessing a human wild-type NGF (hWT), similar but not exactly like the one 
found in a hereditary sensory and autonomic neuropathy type V (HSAN V) disorder. This 
disorder leads to insensitivity to deep pain in homozygous patients, with sensory and 
autonomic functions remaining almost normal. In mice with the hR100E mutation, we found 
similar behavioural outcome; normal peripheral sensory functions but less pain-like 
behaviour when assessing joint pain with gait and weight bearing. 
In summary, this work shows that in order to detect translatable effects on joint pain, models 
need to be robust enough, especially for pharmacological testing, but more important, the 
methods of testing need to be relevant for the study aim. 
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1 INTRODUCTION 
1.1 BACKGROUND 
 
Chronic pain is a major health problem affecting 10-20 percent of the population, resulting in 
marked reduced quality of life for the individual. Pain is also a substantial socio-economical 
problem and the cost for chronic pain in Sweden has been estimated to 87.5 billion SEK in 
medical treatment, loss of productivity and disability (SBU 2006). A large-scale survey 
undertaken in 15 European countries showed that 40% of the people reporting persistent pain 
(> 6 months) had joint pain. OA, followed by RA, is the most common cause of joint pain 
(Breivik et al., 2006). In these conditions, disability and pain upon movement are frequently 
reported to have a significant impact on the quality of life (Rejeski et al., 1996; van Baar et al., 
1998). 
 
Thus the overall aim of my work has been to elucidate the possibility to use measurement of 
weight bearing and gait in rodent models of joint pain, in hopes that it would give results that 
are more predictive for the clinical outcome in trials with patients experiencing joint pain. As 
my interest and motivation is based on many years of looking at animal behaviour, that is where 
my focus lies. So far several new chemical entities have been tested in the clinic based on other 
measurements pre-clinically, such as effects on mechanical or thermal sensitivities, and as these 
attempts have not proven successful my conviction is that new ways of measurements are 
needed. Drug development in the area of chronic pain has hitherto been mostly unsuccessful, 
and there are still few available effective treatments for chronic pain conditions. This is in spite 
of immense resources being spent on developing new molecular targets and testing them, first 
thoroughly in the preclinical setting, and later some selected promising molecules in the clinic. 
Several potential new drug targets have been tested in patients, and despite positive outcomes 
in preclinical models, not many have been progressed to produce drugs that alleviate pain in 
humans. Although the majority of the preclinical targets never reach the stage of testing in 
humans, even those that do mostly failed. This is not a problem only for the pain indication but 
several of the large pharmaceutical companies, including AstraZeneca, have closed down their 
research in the central nervous system (CNS)/pain field and with that all research for new pain 
medication. As I have personal experience of working in projects bringing chemical 
compounds all the way to clinical testing, I feel deeply that whatever my experience could add 
to the possibility of finding new treatment for chronic pain would make my life’s work 
worthwhile.  
 
When I started looking at joint pain models more than twenty-five years ago, not many of the 
models and methods used today were known. Manual scoring to assess guarding behaviour had 
recently been published by Coderre and Wall 1987, and that was what I used in some models 
of monoarthritis. However the results were not satisfactory for me as I could see that scores 
changed over the 4 minute films that I analysed, and there were no suggestions of how to adjust 
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the scores for these temporal changes. New devices to measure static weight bearing 
encouraged me to look also for the possibility to measure as the animal walked, and in 
collaboration with Frank Hamers who developed the CatWalk, the analysis algorithms were 
improved by adding light intensity as an indirect method to measure weight bearing. By using 
this way of assessing the effect of inhibitors of the nerve growth factor (NGF) pathway – which 
worked better than any treatment I had hitherto tested – and of the transient receptor potential 
cation channel subfamily V member 1 (TRPV1) receptor – which had no effect – my belief in 
choosing a model, and even more importantly a mode of measuring effects, that mirrors what 
patients complain about grew stronger.  
 
As OA is the most common reason for joint pain, and no good disease modifying medication 
exists today, these patients have been chosen for many of the clinical trials. Below I will review 
what is known about risks for getting OA, as well as OA pathology and the treatments used for 
OA pain today. Then follows a part where possible mechanisms of pain in OA are discussed. 
The next part describes animal models of joint pain; the ones I have used and some other 
possible models, and different ways of measuring outcome in the animal models.  Finally a part 
on pharmacology, including possible targets for treatment that I have used in my studies. 
1.2 OSTEOARTHRITIS 
1.2.1 Risks for getting osteoarthritis 
What causes the start of processes in the joint that lead to OA is not yet known, but several 
underlying risks for developing OA have been found (Felson et al., 2000; Zhang et al., 2010). 
As in many other joint diseases there is a difference of OA prevalence between women and 
men; females generally have a higher risk at getting OA and it gets more severe compared to 
that in males (Srikanth et al., 2005; Glass et al., 2014). This becomes more obvious as 
patients grow older, and age is a high risk in itself (Zhang et al., 2010; Neogi and Zhang 
2013; Loeser 2013), and perhaps one of the strongest risk factors for OA (Lawrence et al., 
2008). Furthermore fractures of the meniscus and injuries of the cruciate ligaments 
surrounding the knee increase the risk of later getting OA (Englund et al., 2003; von Porat et 
al., 2003; Muthuri et al., 2011), but damage to the meniscus and disruption of the anterior 
cruciate ligament have also been found in OA patients without previous injuries (Hill et al., 
2005; Englund et al., 2003), and could perhaps be another part of the pathology itself. 
Another factor shown to have an impact on the occurrence of OA is body weight, and obesity 
adds to the development of OA (Felson et al., 1988; Niu et al., 2009; Blagojevic et al., 2010). 
The reason for the increased risk may be the obvious increased load on joints, but there are 
also suggestions that the reason is metabolic, as joints that are not loaded such as the hands 
and shoulders are more affected in patients with obesity (Oliviera et al., 1999). In addition, 
there is a large and complex genetic component to the risk of developing OA, and it has been 
reported that the heritability of OA is more than 60%, but differs with respect to the different 
joints (Spector and MacGregor 2004). 
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1.2.2 Osteoarthritis pathology 
Osteoarthritis is a disease involving structures of the entire joint.   
 
Figure 1. A healthy knee joint (left) and a knee joint with advanced osteoarthritis showing 
cartilage loss, joint narrowing and bone spurs. (With permission from Spring Loaded 
Technology. https://springloadedtechnology.com/guide-to-severe-knee-osteoarthritis-
treatment-options/ ) 
 
Destruction of the cartilage was long believed to be the major cause of OA, but inflammation 
of the synovium and synovial membrane, development of osteophytes (“bone spurs”) and 
breakdown of subchondral bone including bone marrow oedema and lesions, “characterized 
by excessive water signals in the marrow space on magnetic resonance imaging or ultrasound” 
according to Eriksen 2015 has also been suggested. The cartilage which in healthy subjects 
serves as a smooth lubricated surface to allow for efficient motion letting the different parts of 
a joint move easily one against the other is where changes are first seen. As reviewed in Loeser 
et al., 2012, the cartilage matrix chondrocytes undergo changes that lead to cell proliferation 
and cluster formation. These cells increase the production of matrix proteins and matrix-
degrading enzymes, including aggrecanases and collagenases, which lead to e.g. matrix 
remodelling. Loeser et al., 2012 state that “once the collagen network is degraded, it appears 
that a state is reached that cannot be reversed”. The clustered chondrocytes, especially, have 
receptors for components of the extracellular matrix and cytokines and chemokines, and when 
activated by those modulate inflammatory and catabolic responses (Loeser et al., 2012).  
A low grade inflammation of the synovium has been found even in the early stages of the 
disease in OA patients, and increased as the OA progresses (Benito et al., 2005; Krasnokutsky 
et al., 2011). In addition, macrophages and lymphocytes have been detected in the synovium 
of over 50% of patients with knee OA (Pearle et al., 2007). There are a number of cytokines 
and chemokines released from these inflammatory cells, including but not restricted to 
interleukin-1 (IL-1), IL-6, IL-8, tumour necrosis factor (TNF), monocyte chemoattractant 
protein-1 (MCP-1) and macrophage inflammatory protein-1 (MIP-1). But, the levels of those 
proteins in OA synovial fluid are not as high as in patients with RA. 
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Both mechanical load and the inflammatory process of OA leads to adaptations of the bone, 
making it less resistant to damage. Bone remodelling is thought to represent attempts to heal 
the bone, and may be the starting point of osteophytes, i.e. bony protrusions at the edge of the 
joint. As a response to the injury, including bone marrow lesions, the tissue is activated and 
new vascular channels grow into the affected bone to start the regeneration (Loeser et al., 
2012). Along the vessels sensory nerves may grow, that are believed to add to the pain 
signalling in OA (Suri at al., 2007). 
1.2.3 Current treatments for osteoarthritis 
Treatments available today for OA do not stop disease progression, but are aimed to alleviate 
the major symptom, pain (Jordan et al., 2003; Zhang et al., 2007; Zhang et al., 2008; Bruyère 
et al., 2014). The only “treatment” with proven efficacy is physical exercise, and both aerobic 
training and strength exercise give the largest effects in relieving pain and improving function 
(Walker-Bone et al., 2000; Bennell and Hinman 2011; Juhl et al., 2014). In addition, for 
patients with obesity, body weight reduction is important and will relieve symptoms. However, 
both exercise and weight reduction necessitates behavioural changes that are difficult to control 
and are challenging for patients as positive results are not immediate, and so the most common 
treatment remains pharmacological. This is mainly pain reducing medication such as 
paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs) and weak opioids (Felson 
2009). But, according to a review by Smith et al., 2016, these treatments are similar in their 
efficacy but can only reduce the pain with about 20%. As the condition proceeds and OA 
reaches a stage with severe pain, excessive degeneration of the joint and increasing levels of 
disability, many go through a total joint replacement. Unfortunately as many as 15%-30% of 
those patients still report considerable pain (Hawker 2006; Wylde et al., 2011). As OA is a 
chronic condition, pain medication is needed for many years. The long-term pharmacological 
treatments recommended today come with considerable complications; gastrointestinal, 
cardiovascular and renal adverse side effects for NSAIDs and nausea, constipation and 
dizziness for opioids (Avouac et al., 2007; O´Niel et al., 2012; Pelletier et al., 2016). When 
considering this, it is obvious that there is a great need for better medication. 
Drug development in the area of chronic pain has been insufficient in general, and there are 
currently few available effective treatments. Thus, it is critical to increase our understanding 
for how chronic pain is regulated in order to identify new biological targets. Several potential 
new drug targets have been tested in patients, and despite positive outcomes in preclinical 
models, very few have been progressed to produce drugs to alleviate pain in humans. Hence, 
it is critical to improve our tools for assessing potential new targets in a way so that they 
predict clinical efficacy. 
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1.3 PAIN MECHANISMS 
 
In the joint, the ligaments, fibrous capsule, meniscus, periosteum and synovial layer are 
innervated by sensory A, A- and C-fibres and noxious (pain) sensation can be evoked from 
these structures (Schaible et al., 2009). However the cartilage is not innervated and it is believed 
that no sensation can be emitted from cartilage in healthy subjects. Upon activation of the 
sensory nerves, signals are sent to the spinal cord dorsal horn where these primary afferents 
couple to second order neurons or interneurons, which project the information towards the 
brain. Patients with joint inflammation experience pain during normal movement of the joint 
and even gentle pressure, e.g. palpation, often elicits pain. The increase in sensitivity is thought 
partly to depend on inflammatory factors released locally in the joint. For example 
prostaglandins, bradykinin, growth factors such as NGF, tumour necrosis factor and 
interleukins reduce the threshold for activation and increase the responsiveness of the sensory 
neuron, giving rise to pain sensations in response to both noxious and non-noxious stimuli 
(termed hyperalgesia and allodynia, respectively) (McMahon et al., 2005).  
 
There is mounting evidence that there is a comparable release of similar mediators in the spinal 
dorsal horn, where these factors mediate spinal facilitation of pain processing, further 
amplifying nociceptive signals conveyed to the brain. Hence, many factors that are involved in 
the inflammatory process at the peripheral site may also drive spinal sensitization. It is 
important to note that an inflammatory response normally is self-limiting, serving as a 
protective mechanism in response to injury or infection. All the same, there are many long-
term or chronic conditions in which inflammation does not resolve, and this may have a 
significant impact on the sensory neurons and lead to chronic pain.  
 
Lately many studies have shown that sensitization of the central pain system occurs which 
contributes to pain in preclinical models of OA (Abaej et al., 2016; Knazovicky et al., 2016), 
and in chronic OA pain patients (Akinci et al., 2016; Moss et al., 2016). Both central 
integration of the pain signal and the descending pain pathways may play a part in the 
sensitization (Arendt-Nielsen et al., 2015; Sikander et al., 2016). The signs include increased 
spread of tenderness in areas not associated with the affected joints, shown e.g. by decreased 
thresholds for mechanical sensitivity. Additionally, there are reports that OA with time can 
manifest in neuropathic pain states (Dimitroulas et al., 2014; Roubille et al., 2014). 
1.4 ANIMAL MODELS OF INFLAMMATORY PAIN AND OSTEOARTHRITIS 
 
In order to study chronic inflammatory joint pain, the choice of animal model is important. The 
optimal model would be one that completely mirrors what is found in human patients, but as 
even in those there is a range of different structural and sensory changes, this becomes nigh 
impossible. Several aspects then form the basis for which model to choose. If the main focus 
is to look at structural changes the model needs to be one showing similar modifications, e.g. 
in cartilage, synovium and subchondral bone, as those seen in at least a subgroup of patients. 
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As my interest lies in measurement of pain-like behaviour, the models chosen for my work 
need to give significant effects in tests aimed at assessing mechanical or thermal sensitivity, or 
even more important, in tests attempting to measure spontaneous or non-evoked pain. Several 
widely used animal models of arthritis-like pain involve intra-articular ankle or knee injection 
of chemical agents such as carrageenan and Freund’s complete adjuvant (FCA/CFA).  
1.4.1 Carrageenan 
The carrageenan-induced monoarthritis produces a pronounced inflammatory reaction where 
granulocytes rapidly infiltrate the site of injection and which gives nociceptive behaviour in 
rats that lasts for 24-48 hours. It contains a sulphated mucopolysaccharide derived from 
Chondrus crispus or from red Scottish seaweed (Smith and Cook 1953) and a single intra-
articular injection can reduce the proteoglycan content and the rate of proteoglycan synthesis 
in the cartilage (Lowther and Gillard 1976; Santer et al., 1983). In 1992, Tonussi and Ferreira 
described how carrageenan injected into the rat knee joint caused a concentration-dependent 
incapacitation which reached a maximum within 24-48 hours after the injection. In addition, it 
caused a pronounced swelling of the joint. As there is a possibility that the swelling itself could 
cause sensory activation, dextran was injected intra-articularly into the knee joint in another 
group of rats. However dextran, a substance that causes oedema but does not involve 
inflammatory mediators or cellular infiltration, failed to induce any incapacitation.  
1.4.2 FCA 
FCA/CFA is a mixture of mineral oil and inactivated, dried mycobacteria, which produces a 
more prolonged stimulation of cell-mediated immune responses leading to a local joint 
inflammation that lasts for up to two weeks or more in rats. In 1992 Butler et al. described a 
method to induce an inflammation locally in the ankle joint of one hind paw in rats. This new 
technique of intra-articular injection led to a restricted monoarthritis, not the generalized 
polyarthritis which is a result of injecting FCA subcutaneously (Waksman et al., 1960; Pearson 
et al., 1960; Pearson 1963). In contrast to the carrageenan model, injection of FCA to the rat 
ankle joint leads to a number of structural changes such as pannus formation, bone remodelling 
and cartilage erosion (Brenner et al., 2006; Hashmi et al., 2010).  
1.4.3 MIA 
A low-grade inflammatory model, first described by Kalbhen DA in 1987: “Chemical model 
of osteoarthritis – a pharmacological evaluation” is induced by the intra-articular injection of 
monosodium iodoacetate (MIA) that inhibits glyceraldehyde-3-phosphate dehydrogenase and 
disrupts the chondrocyte glycolysis leading to ensuing cell death. In the MIA model the major 
inflammatory phase resolves within a week, while collagen degradation progressively makes 
the cartilage thinner until the underlying bone emerges (Guzman et al., 2003; Fernihough et al., 
2004).  
 
These three rat models are commonly used in the pain research field and have the advantage of 
a predictable onset, high success rate and fast disease progression. They are also the models 
that form the basis for my work. However, it has been debated whether using longer-lasting 
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animal models would generate changes in the sensory system that more closely mimic changes 
in the mechanisms of chronic arthritis-induced pain in humans, and efforts have been made to 
find models that more resembles osteoarthritis.  
1.4.4 Surgical OA models 
One of the most common ways of modelling OA to understand the histological consequences 
is by inflicting a surgical injury to the knee joint in different animal species. Several procedures 
have been described, such as meniscal tear, partial or total meniscectomy and anterior cruciate 
or other ligament transection, and all could be assumed to model aspects of traumatic causes 
of OA in humans. By inflicting destabilization of the knee joint in rats or mice, similar 
structural changes to those in patients have been described, such as loss of cartilage, occurrence 
of osteophytes and subchondral sclerosis (Fernihough et al., 2004; Janusz et al., 2002; Bove et 
al., 2006). In addition, several of these models show development of mechanical 
hypersensitivity and guarding of the injured limb. When comparing to the slowly evolving 
human OA, these models have the advantage of a slower induction (weeks) and a longer lasting 
(months) hypersensitivity than those chemically induced. Although differing in the pathology, 
surgical models could potentially be used to evaluate new mechanisms and targets for treatment 
of joint pain. 
1.4.5 Joint loading model 
Recently, a mouse model focusing on increased loading of the knee joint was developed and 
validated (De Souza et al., 2005; Poulet et al 2011, ter Heegde et al 2019). This model was 
induced by putting one hind leg of an anaesthetized mouse in a holder, where the knee joint 
was placed into one cup and the ankle joint into another. A small baseline load, 2N, kept the 
leg in place, and the load was then increased to 9-11N for 0.05 seconds every 10 seconds. The 
peak loading was repeated 40 times in one session, and three sessions per week was performed 
for two consecutive weeks. The model results in cartilage lesions and loss of structural integrity 
of the lateral femur (Poulet et al 2011), as well as development of mechanical hypersensitivity 
and reduced weight bearing of the affected hind limb, lasting for more than six weeks (ter 
Heegde et al 2019).  
1.4.6 Spontaneous models 
Spontaneously occurring knee OA has been observed in several animal species, including 
some strains of mice, guinea pigs and hamsters (Walton 1979; Nordling et al., 1992; 
Silverstein and Sokoloff 1958; Bendele and Hulman 1988). Even though one may think that 
these animals would be the best in which to study OA, it is impossible to know exactly when 
symptoms appear in the individual mouse or guinea pig. As a result, planning studies are 
difficult and the time to conduct a study can become far longer than recourses allow for.  In 
addition, the pathogenesis of this OA is not completely understood (Bendele 2001). These 
facts make well powered, planned and controlled tests expensive and challenging, if not 
almost impossible. 
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1.5 ASSESSMENT OF PAIN-LIKE BEHAVIOUR IN RODENTS 
 
Assessment of pain-like behaviour in rodents remains a challenge, more so in mice than in rats. 
Behavioural testing in rodent pain models can be divided into two categories: performer 
stimulus-evoked, and non-evoked or spontaneous behavioural responses. The traditional way 
to test is by establishing a threshold where the animal reacts with a behaviour that can be 
assumed to be a response to a nociceptive signal – an evoked response to mechanical, thermal 
or cold stimuli.  
1.5.1 Sensory testing 
1.5.1.1 Mechanical sensitivity 
As far back as 1896 Max von Frey in his dissertation described the use of human and horse 
hairs of different stiffness for detecting mechanical sensation, and since then similar artificial 
hairs have been named von Frey filaments (von Frey 1896). The traditional material used for 
the test filaments is synthetic fibres such as nylon, but as those are sensitive to changing 
temperature and humidity (Andrews 1993; Ängeby Möller et al., 1998) new hairs made of glass 
fibre, the von Frey Optihairs, have also been introduced (Fruhstorfer et al., 2001). Several 
different approaches have been used to establish a threshold: application of one or more 
selected filaments for a specified number of times and counting percentage of responses to each 
filament; application of filaments with increasing force to find the one where the animal starts 
responding; or using the up-down technique first described by Dixon in 1980, and modified by 
Chaplan et al. 1994. Whichever method of testing that is chosen, they are all dependent on a 
performer and his or her subjective decision of when a withdrawal response is achieved. To 
overcome the subjectivity attempts have been made to develop more objective methods, using 
an electronic von Frey filament which is applied to the paw with increasing force and that gives 
a threshold automatically as the paw is withdrawn (Ängeby Möller et al., 1998; Cairns et al., 
2002). For testing sensitivity to pressure in deeper lying tissues several devices have been 
presented, such as that described by Randall and Selitto (Randall and Selitto 1957).  
In my work before becoming a PhD student I have tested mechanical sensitivity in rats with 
both traditional nylon von Frey filaments (Stoelting) and von Frey Optihair, as well as an 
electronic von Frey device developed by Somedic (Ängeby Möller et al., 1998). The up-down 
method to calculate a withdrawal threshold was always used, as this method seems to have 
become the method of choice for many pain researchers. However the majority of these studies 
were performed on rats subjected to models of neuropathic pain. In my present work the more 
stable von Frey Optihairs have been used. 
1.5.1.2 Thermal sensitivity 
Testing sensitivity to heat comes with similar difficulties. Thus directing a light beam towards 
the plantar skin of a paw to assess the latency until withdrawal was described by Hargreaves 
1988 (Hargreaves et al., 1988), but as the skin can have varying basic temperature which affects 
the result it can be difficult to establish what has more impact – the increase in temperature or 
the starting skin temperature (Tjølsen et al., 1989). When the baseline skin temperature is high, 
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the latency until withdrawal is short, while it takes considerably longer time until withdrawal 
if the skin temperature in the beginning of testing is low (Hole and Tjølsen 1992).  
1.5.1.3 Cold sensitivity 
Cold sensitivity is often measured with the application of an acetone drop (De la Calle et al., 
2002; Dowdall et al., 2005), but spraying of ethyl chloride has also been reported (Gustafsson 
and Sandin 2009). These applications are considered to be pain-like if the animal starts licking 
and/or shaking the affected paw. The decrease in skin temperature following application is 
much larger for ethyl chloride, but in both cases the amount applied is hard to control as is the 
exact site of stimulation.  
1.5.2 Assessment of non-evoked or spontaneous behaviours 
Still, for models of arthritis it is also possible to assess spontaneous or non-evoked behavioural 
responses, which probably more reflect the sense of pain in the animals. This has been the main 
focus for my work, as I believe that this could mirror what patients experience in the clinic. I 
have specifically tried to find ways of measuring pain-like behaviour of animals in locomotion, 
as that is the major complaint in patients with joint pain. Many ways of measuring total 
locomotor activity exist, but there are equally many reasons for a decrease in locomotor 
activity, making this way of testing specific models difficult.  
1.5.2.1 Static weight bearing 
When only one hind paw has been subjected to an induction of arthritis, scoring of guarding 
behaviour during standing and walking was first described by Coderre and Wall (Coderre and 
Wall 1987). Scoring is by its nature subjective and many are those that have come up with 
methods trying to make assessment of guarding more objective. By fitting force plates in the 
floor of a box the weight load of the two hind paws could be measured (Schött et al., 1994), 
and later the Incapacitance tester was introduced where animals stand with the two hind paws 
on force plates while the front paws are placed on a ramp (Bove et al., 2003). In both methods, 
placing an animal in the box or holder induces stress and needs training before a trustworthy 
result can be obtained, and varying placements of the tail or the animal leaning onto the side of 
the box can distort the readout.  
1.5.2.2 Stationary weight bearing 
Recently another device has been introduced, the Advanced Dynamic Weight Bearing (DWB), 
where a sensor mat measures the load and a camera fitted on top of the box films the animal 
simultaneously making it possible to validate the detection of each paw’s placement (Tetreault 
et al., 2011). The animal is allowed to move within a restricted area during a selected period to 
give weight bearing data of all four paws both when standing and when rearing.  
1.5.2.3 Gait and weight bearing during locomotion 
As movement-induced pain is a major complaint in patients with chronic pain from the joints, 
exploring behaviour in rodents with and without joint inflammatory pain during locomotion 
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may give added information of mechanisms and treatment. Several ways to do this have been 
introduced, but few have yet been extensively used.  
 
Tonussi and Ferreira (Tonussi and Ferreira 1992) invented a setup where rats were fitted with 
specially designed metal gaiters wrapped around the paw of interest, and the time of contact 
with a mesh floor covering a rotating cylinder was then assessed. With this device they could 
establish the pharmacological effects of some analgesic drugs after injection of carrageenan 
into one knee joint of rats. By attaching an electrode between the pads of the hind paw the 
method was improved and the rats could walk more freely on the cylinder (López-Muñoz et 
al., 1993). Still these were setups that were complicated and difficult to manufacture to 
become commercially available.  
 
Another approach was introduced – to use video recordings from underneath to assess 
walking rats. To make the paw contact areas more visible a frosted plexiglass surface was 
suggested, which gave several new parameters of all four paws such as gait stance – the time 
from initial contact of a paw with the floor until lifting the paw as next step was started 
(Walker et al., 1994). The weight bearing during locomotion turned out to be more difficult to 
assess. By adapting a technique described by Betts and Duckworth in 1978 for measuring 
human plantar pressure, based on white light entering the long edges of a 6 mm thick glass 
where the light was internally reflected between the two surfaces of the glass until e.g. a rat 
paw was placed which then scattered the light, K Clarke built a walkway that could study the 
paw contact patterns of rats (Clarke 1992). He later combined it with load measurements 
underneath two 10x5 cm areas at half-way of the walkway, one for each side of the glass 
floor, and showed that the coefficient of correlation between load cell output and output from 
the scattered light of a paw in contact with the floor was 0.92 (Clarke 1995). Using this setup, 
effects of the MIA model of OA in rats, as well as detailed load and temporal aspects of 
mouse locomotion were assessed (Clarke et al., 1997; Clarke and Still 1999; Clarke and Still 
2001).  
 
Hamers et al., 2001 introduced a walkway with light entering the long edge of a glass floor, 
the CatWalk, where a semi-automated interactive analysis algorithm gave a large number of 
parameters assessed in rats with spinal cord injury (step sequence distribution, regularity 
index, print area, maximum contact area during stance, base of support, stride length, swing 
duration, and duration of tail dragging and abdominal dragging). Later the amount of light 
intensity per pixel was added to make it possible also to indirectly assess weight bearing in 
rats with a model of neuropathy (Vrinten and Hamers 2003). Similar setups have followed, 
manufactured by several companies focusing on devices for animal behavioural research. 
 
Others tried a slightly different technique, such as that of the TreadScan (CleverSys) where 
rodents’ paws are filmed from underneath as they walk on a sliding treadmill belt which can 
be controlled for the speed of the animal as it is forced to move at the same speed as the belt 
(Beare et al., 2009). Temporal and all area-dependent parameters can be assessed, and it’s 
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suggested that changes in weight bearing are indirectly detected as the paw is pressed against 
the floor and the colour of the plantar skin becomes lighter when more of the small capillaries 
are obstructed. 
 
Still, the most common tests rely on tester-evoked responses such as assessment of mechanical 
or thermal hypersensitivity by generating a withdrawal from the source of stimulus. According 
to Mogil and Crager 2004, 90% out of 259 articles between 2000 and 2004 in the journal “Pain” 
that described animal studies of neuropathic and inflammatory pain in which behavioural 
testing was included, exclusively measured changes in threshold or response to evoked stimuli. 
A number of drugs, for example neurokinin-1 (NK-1) antagonists and transient receptor 
potential vanilloid 1 (TRPV1) antagonists (Svensson et al., 2010) have failed in clinical trials 
despite repeatedly showing effect against hypersensitivity states. There is an increasing 
suspicion that tester-evoked tests do not reflect the human joint pain problem, and that non-
evoked behaviours such as locomotion, guarding of the effected limb, reduced weight bearing 
and gait changes may provide a better correlation to the human pain state. 
 
Hence, it is critical to improve our tools for assessing potential new targets in a way so that 
they predict clinical efficacy. From a pain perspective, it is essential to evaluate models that 
best mimic the human pain condition, and perhaps even more important, which endpoints to 
use when measuring pain behaviour. As movement-induced pain is a problem for arthritis 
patients we have investigated if gait and weight bearing can be used as endpoints that better 
mimic the pain state in humans, and thus hopefully better predict results in clinical trials.  
1.6 PHARMACOLOGY 
 
Pharmacological evaluation was performed in the present work, to elucidate the usefulness of 
the chosen models and measurement methods, and include several NSAIDs, paracetamol, 
pregabalin and opioids. In addition new chemical entities targeting the NGF pathway – both an 
anti-NGF antibody and two pan-Trk inhibitors; inhibitors of tropomyosin receptor kinases 
(Trk) A, B and C – and an inhibitor of the TRPV1 receptor have been evaluated. Thus, below 
I describe some of the characteristics of these pharmacological agents. 
1.6.1 Drugs inhibiting NGF and its receptor TrkA  
Several attempts have been made to find suitable pharmacological treatment for chronic pain 
using the NGF/TrkA pathway as target. One of the most encouraging is the development by 
Pfizer of a monoclonal antibody that inhibits NGF, Tanezumab, which shows efficacy both in 
rodent models (Shelton et al., 2005) and in patients with OA (Lane et al., 2010). The reduction 
of knee pain in the patients while walking was more pronounced than that being achieved by 
commonly used NSAIDs (Schnitzer et al., 2015). NGF is a member of the neurotrophin family 
and activates the TrkA with high affinity, and the p75 receptor with low affinity. It is essential 
for axonal growth and survival, especially in the neonatal time period, and later in life plays a 
major role in pain processing. When tissue is injured or inflamed, NGF is released from mast 
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cells, macrophages, keratinocytes and T-cells (Figure 2; for review see Pezet and McMahon 
2006). Of note, when activated, the TrkA receptor forms a complex with NGF and is 
internalized and transported to the nucleus where it promotes expression of a number of other 
pain-associated receptors, such as CGRP, TRPV1, P2X3 and ion channels neurotransmitters 
(Heppenstall and Lewin 2000; Winston et al., 2001; Bonnington and McNaughton 2003; Pezet 
and McMahon 2006).  
 
 
Figure 2. Neurotransmitters, receptors and ion channels that are modulated and up-regulated 
by NGF binding to TrkA-positive primary afferent sensory nerve fibres are shown in (A). In 
(B), cells that release NGF during injury or inflammation is shown. (Reprinted with permission 
from Mantyh et al., 2011) 
 
Injection of NGF into the paw causes hypersensitivity to mechanical stimuli in rats (Lewin and 
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Mendell 1993), as does injection into the masseter muscle in humans, where pain intensity also 
increased when chewing and yawning (Svensson et al., 2003). NGF is elevated in synovial 
fluid from patients with RA (Halliday et al., 1998), however the effect of NGF blockage on 
pain in RA animal models or RA patients has not been extensively studied. 
1.6.2 Inhibitor of the TRPV1 receptor 
The TRPV1 receptor is activated by heat and acidic environment containing increased levels 
of H+ (Caterina et al., 1997). Capsaicin, the ingredient giving food some of its “hot” taste, is 
an agonist of TRPV1, and injecting capsaicin into human or animal skin results in an intense 
but short-lasting pain (Lamotte et al., 1992; Kinnman and Levine 1995). Activation of the 
TrkA receptor by NGF leads to a rapid increase in TRPV1 receptor membrane expression on 
primary sensory neurons (Zhang et al., 2005; Stein et al., 2006) and selective antagonism of 
the TRPV1 receptor has been suggested as a potential drug target for treatment of joint 
inflammation (Keeble et al., 2005). A model of heat pain that is commonly used in clinical 
trials is the ultraviolet (UV) burn, and TRPV1 antagonists have been shown to alleviate this 
pain. However trials with TRPV1 antagonists in patients with OA failed as no effect on pain 
was found (Svensson et al., 2010; Segerdahl et al., 2010).  
1.6.3 Non-steroidal anti-inflammatory drugs  
One of the mediators produced in inflamed tissue is prostaglandin E2 (PGE2). The origin is 
fatty acids derived from cell membrane, and it is synthesized when the tissue is injured by 
physical trauma or when cytokines or growth factors such as NGF signal the need for tissue 
inflammation and repair. The production of prostaglandins requires several enzymes, one of 
which is cyclooxygenase (COX), the enzyme inhibited by NSAIDs. There are two different 
variants of COX; COX-1 and COX-2. COX-1 is believed to be constitutive, whereas COX-2 
is predominantly produced in inflammation. Production of PGE2 leads to the well-known 
symptoms of inflammation – pain, swelling and fever.  
The first report of the effects of COX inhibition in humans through use of willow bark was 
found in: Stone E. “An account of the success of the bark of the willow in the cure of agues” 
(Stone 1763), and reported in Vane and Botting 1998. However willow bark, and other plant 
derived decoctions containing COX inhibiting salicylates have been used for thousands of 
years, and are known from the ancient Egyptians through the Ebers papyrus, and ancient 
Greeks in recommendations by Hippocrates. Still today, COX inhibitors are the most 
commonly used pain relieving drugs and are recommended for many conditions that have an 
inflammatory component, including joint pain originating from e.g. OA.  
1.6.4 Opioids 
Inhibition of the opioid receptor has been used to relieve pain for thousands of years as well, 
but not until the last century have there been an opportunity to reveal the mechanism behind 
the effect. Today we know that opioids preferentially act on the µ opioid receptor subtype, a 
G-protein coupled receptor which has effects on ion-channels in the membrane of nervous 
tissues, resulting in a reduction of neuronal excitability and transmitter release (for review see 
Corbett et al., 2006).  
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1.6.5 Paracetamol 
In spite of its widespread use and good effect on pain and fever, but not inflammation, the 
mechanism of paracetamol is still not known. 
1.6.6 Pregabalin 
Although introduced as an anti-epileptic drug, the group of drugs that pregabalin belongs to 
also have an effect on pain. The mechanism, believed to be reduction of neurotransmitter 
release through binding to the α2δ1 subunit of the voltage-gated calcium channels, leads to less 
neural activity (for review see Sills GJ 2006). 
 
In summary, one aim of this project was to test the predictive value of the rat and mouse 
models of joint inflammation and surgical OA and the described behavioural endpoints using 
the NGF/Trk mechanism as a positive target, TRPV1 as a target without effect and compare 
those to effects by medications used in treatment of arthritis today, e.g. NSAIDs, COX-2 
selective antagonists, paracetamol and opioids. In addition, we wanted to explore the role of 
NGF in arthritis-induced pain and arthritis pathology. 
1.7 MUTATIONS OF NGF 
 
Mutations of NGF or the NGF receptor TrkA leads to congenital insensitivity to pain 
(Nagasako et al., 2003). The resulting condition is named hereditary sensory and autonomic 
neuropathy (HSAN), and one of these mutations was detected in Sweden; the type V (HSAN 
V; Minde 2006). Peripheral nerves in homozygous patients show reduced amounts of Aδ and 
C fibres. These patients develop severe joint problems, e.g. Charcot joints, but unlike other 
types of HSAN, no mental retardation or lack of sweating ability has been found. The exact 
mutation was found to be a replacement of an amino-acid in the NGFß gene, such that a basic 
arginine was exchanged for a non-polar tryptophan (Einarsdottir et al 2004), which then 
produced the NGFR100W protein. Attempts have been made to breed mice with the exact same 
mutation, but these were not viable unless the mother received normal NGF from gestation 
until end of lactation, and the pups were given NGF from birth. Even with this treatment, the 
body weight of these mice pups did not increase after the age of three weeks (Testa et al., 2019). 
AstraZeneca bred a mouse carrying a similar mutation, the R100E, where arginine was replaced 
by glutamic acid. These mice, who survive until adulthood, were donated to our group at KI 
and we were fortunate to be able to test them extensively to evaluate whether these mice show 
a phenotype similar to the homozygous patients with HSAN V found in the north of Sweden. 
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2 AIM OF THESIS 
The overall aim of the study was to investigate whether behavioural endpoints exist that mimic 
the movement-induced ongoing pain state in arthritis patients, to give a better predictive value 
for clinical trials. Two specific aims of this thesis were: 
1. Examine if alterations in gait and weight bearing can be used as outcome measure of 
spontaneous pain in animal models of joint inflammation 
1.1. Investigate if and how joint inflammation alters standing weight bearing (static), 
weight bearing during voluntary and forced locomotion (dynamic) and gait in animal 
models of arthritis 
1.2. Examine if arthritis-induced changes in static and dynamic locomotion and gait are 
normalized by conventional pain relieving drugs 
2. Explore the role of NGF and the ion channel TRPV1 in arthritis-induced spontaneous pain 
2.1. Investigate if NGF blockade and TrkA and TRPV1 antagonists reverse arthritis-
induced changes in weight bearing and gait 
2.2. Investigate if mice with non-functional NGF develop arthritis pathology and/or if they 
are protected from arthritis-induced changes in gait and weight bearing
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3 MATERIAL AND METHODS 
3.1 ANIMAL MODELS 
3.1.1 Animals 
All animal experiments were performed according to regulations and approved by the Swedish 
local ethical committees. Animals were housed three to six per cage in transparent Macrolon® 
cages with food and tap water ad libitum and lighting controlled.  
Rat strains included Sprague-Dawley (Paper I, II, III and IV), Lewis (Paper III, IV and VI) 
and Wistar (Paper V), and all studies with rats were done in males. The behavioural 
experiments were a continuous process that took place over several years. Due to parvovirus 
infection in the breeding facility at the animal vendor affecting the availability of rat strains, 
the studies were undertaken in three different rat strains, and Sprague–Dawley rats from two 
different breeding facilities. Although not examined in a systematic fashion, some variance in 
duration of ankle joint inflammation in response to the FCA was noted; however the overall 
behavioural response was similar.  
Wild-type C57BL/6JRj mice (Paper VII and VIII) and C57BL/6 mice, of both genders, 
genetically modified by a knock-out of the mNGF, followed by either a knock-in with a wild-
type human NGF or with the hNGF containing the mutation (hR100E) in the coding region of 
the NGFß gene, replacing arginine with glutamic acid (Paper VIII) were used.  
3.1.2 Chemically-induced monoarthritis models 
All joint injections were done while the animals were deeply anaesthetized using 4-5% 
isoflurane. The injection was completed in less than one minute, and the animals woke up 
within two to three minutes. 
3.1.2.1 Carrageenan-induced monoarthritis 
Lambda-carrageenan (Sigma-Aldrich, Sigma Chemicals Co. St Louis, MO, USA) was 
dissolved in physiological saline. Forty to fifty µl was injected into one hind limb ankle joint 
in rats, containing 0.47, 0.94, 1.9, 3.8, 7.5, 15 or 30 mg/ml, for a concentration effect study in 
Paper II, and 7.5 mg/ml was chosen for comparison between ankle and knee joint injection 
and for pharmacological studies in Paper I and II. 
3.1.2.2 Complete Freund´s adjuvant-induced monoarthritis 
FCA/CFA was prepared by adding 100 mg of Mycobacterium tuberculosis (Difco 
Laboratories) to 12.5 ml of Freund´s incomplete adjuvant and dilute to make the different 
concentrations (0.12, 0.25, 0.50, 1.0, 2.0, 4.0, 8.0 mg/ml) injected with 50 µl into one hind limb 
ankle joint in the concentration effect study in paper II. CFA (Sigma-Aldrich, Sigma 
Chemicals Co. St Louis, MO, USA) containing 1.0 mg/ml Mycobacterium tuberculosis was 
chosen for comparison between ankle and knee joint injection (Paper II), and for 
pharmacological studies in rats (Paper II, III, IV and V). In mice, CFA (1.0 mg/ml; Sigma-
Aldrich or 10 mg/ml; Chondrex) was injected in volumes of 5 µl or 10 µl into one hind limb 
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ankle joint (Paper VI). In Paper VIII, CFA (10 mg/ml, Chondrex) was injected into one ankle 
joint in a volume of 5 µl, and 10 µl was injected into one knee joint.  
3.1.2.3 Sodium monoiodoacetate-induced monoarthritis 
Rats were injected into one hind limb ankle or knee joint with 25 µl (Paper III) or 50 µl (Paper 
VI) solution containing 2 mg sodium monoiodoacetate (MIA; Sigma) dissolved in 
physiological saline. 
3.1.3 Anterior cruciate ligament transection model 
Surgical destabilization of the left knee joint in mice (Paper VII) was established by 
transection of the anterior cruciate ligament (ACLT) under deep anaesthesia, and assured by 
controlling rotational capacity. Buprenorphine was administered post-surgery as analgesic. 
3.2 DRUGS AND DRUG DELIVERY 
 
Table 1. An overview of the drugs used  
 
DRUG PAPER SPECIES ROUTE DOSES 
(MG/KG) 
DOSES 
(µMOL/KG) 
INDUCTION 
AGENT 
MEDI-578 Paper IV Rat i.v. 0.03, 0.1, 0.3, 
3.0, 30 mg/kg 
 CFA 
 Paper VII Mouse s.c. 0.3, 1.0, 3.0 
mg/kg 
 CFA 
AZ6623 Paper IV Rat p.o.  10, 30, 100 
µmol/kg 
CFA 
     30, 60, 120 
µmol/kg 
Carrageenan 
AZ7092 Paper IV Rat p.o.  1.0, 3.0, 10 
µmol/kg  
CFA 
     2.0, 6.0, 20, 60 
µmol/kg 
Carrageenan 
AZD1386 Paper IV Rat p.o.  100 µmol/kg CFA 
       
NAPROXEN Paper II Rat p.o.  1.0, 10, 100 
µmol/kg 
Carrageenan 
 Paper IV Rat p.o.  7.5, 30, 90 µmol/kg CFA 
 Paper V Rat p.o. 2.5, 7.6, 11.7 
mg/kg 
 CFA 
IBUPROFEN Paper II Rat p.o.  30, 100, 300 
µmol/kg 
Carrageenan 
 Paper IV Rat p.o.  100, 300 µmol/kg CFA 
DICLOFENAC Paper II Rat p.o.  1.0, 3.0, 10 
µmol/kg 
Carrageenan 
ROFECOXIB Paper I Rat p.o. 2.4, 9.4 mg/kg 7.5, 30 µmol/kg Carrageenan 
 Paper IV Rat p.o.  30, 100, 300 
µmol/kg 
CFA 
VALDECOXIB Paper IV Rat p.o.  10, 30, 100 
µmol/kg 
CFA 
MORPHINE Paper I Rat s.c. 1.2, 4.8 mg/kg 3.75, 15 µmol/kg Carrageenan 
OXYCODONE Paper II Rat s.c.  1.0, 3.0, 10 
µmol/kg 
Carrageenan 
PARACETAMOL Paper II Rat p.o.  1000, 2000, 4000 
µmol/kg 
Carrageenan 
PREGABALIN Paper V Rat p.o. 10, 30 mg/kg  CFA 
       
  19 
3.2.1 Drugs interfering with the NGF-Trk pathway 
The monoclonal NGF antibody MEDI-578 was provided by AstraZeneca, MedImmune, 
dissolved in 50mM sodium acetate and 100 mM sodium chloride and given to rats in a volume 
of 1 ml/kg intravenously at 0.03, 0.1, 0.3, 3.0 and 30 mg/kg, (Paper IV). In studies with mice, 
MEDI-578 (0.3, 1.0 and 3.0 mg/kg) was injected subcutaneously in a volume of 5 ml/kg (Paper 
VII).  
The two pan-Trk antagonists AZ6623 (10, 30, 60, 100 and 120 µmol/kg) and AZ7092 (1.0, 
2.0, 3.0, 6.0, 10, 20 and 60 µmol/kg) were provided by AstraZeneca, dissolved in 0.5% 
hydroxypropylmethylcellulose (HPMC) and 0.1% Tween 80, and administered to rats per os 
in a volume of 5 ml/kg (Paper IV).  
3.2.2 Drugs interfering with the ion channel TRPV1 
AZD1386, a TRPV1 antagonist, was provided by AstraZeneca, suspended in 5% 
hydroxypropyl-ß-cyclodextrin (HBC), 0.2% (w/v) sodiumlaurylsulphate (SDS), 1% (w/v) 
polyvinylpyrrolydone (PVP), 0.25 sodium citrate in water, and administered to rats per os in a 
volume of 5 ml/kg at 100 µmol/kg (Paper IV). 
3.2.3 Non-steroidal anti-inflammatory drugs 
Naproxen (Sigma-Aldrich) was dissolved in physiological saline and administered to rats per 
os in a volume of 2 ml/kg in doses of 1.0, 10 and 100 µmol/kg, (Paper II), in a volume of 5 
ml/kg in doses of 7.5, 30 and 90 µmol/kg (Paper IV), and in a volume of 3 ml/kg in doses of 
2.5, 7.6 and 22.7 mg/kg (Paper V).  
Ibuprofen (synthesized at AstraZeneca) was dissolved in physiological saline and administered 
to rats per os in a volume of 5 ml/kg in doses of 30, 100 and 300 µmol/kg (Paper II), and 
ibuprofen (Sigma-Aldrich) was dissolved in physiological saline and administered in doses of 
100 and 300 µmol/kg (Paper IV). 
Diclofenac (Sigma-Aldrich) was dissolved in physiological saline and administered to rats per 
os in a volume of 5 ml/kg in doses of 1.0, 10 and 100 µmol/kg, (Paper II). 
Rofecoxib (VIOXX, Merck Sharp & Dohme), 2.4 and 9.4 mg/kg (7.5 and 30 µmol/kg) in 
suspension and diluted with water, given to rats per os in a volume of 8 ml/kg (Paper I). In 
Paper IV rofecoxib (30, 100 and 300 µmol/kg) synthesized at AstraZeneca was suspended in 
1% microcrystalline cellulose/sodiumcarboxymethyl cellulose (MCC/NaCMC)+0.6% soy 
lecithin (Lipoid S100) in water and given to rats per os in a volume of 5 ml/kg.  
Valdecoxib (Kemprotec), 10, 30 and 100 µmol/kg was suspended in 1% MCC/NaCMC+0.6% 
soy lecithin (Lipoid S100) in water and given to rats per os in a volume of 5 ml/kg (Paper IV). 
3.2.4 Opioids 
Morphine (Apoteksbolaget, Göteborg, Sweden), which binds preferentially to the µ opioid 
receptor, in doses of 1.2 and 4.8 mg/kg (3.75 and 15 µmol/kg), was dissolved in physiological 
saline, injected s.c. in a volume of 1.0 ml/kg (Paper I).  
Oxycodone (Sigma-Aldrich), was dissolved in physiological saline and administered to rats 
subcutaneously in a volume of 2 ml/kg in doses of 1.0, 3.0 and 10 µmol/kg (Paper II). 
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3.2.5 Other drugs 
Paracetamol (Fluka), was dissolved in 0.5 % methyl cellulose and given to rats per os in a 
volume of 5 ml/kg in doses of 1000, 2000 and 4000 µmol/kg (Paper II). 
Pregabalin (Toronto Research Chemicals Inc.), which binds to the α2ß subunit of voltage-gated 
calcium channels to reduce the calcium current after activation (Bauer et al., 2010), was 
dissolved in physiological saline to get 10 and 30 mg/kg and given per os in a volume of 3 
ml/kg in Paper V. 
3.3 ASSESSMENT OF PAIN-LIKE BEHAVIOUR 
3.3.1 Gait and weight bearing during locomotion 
Assessment of gait and weight bearing parameters were based on letting animals voluntarily 
cross an enclosed walkway with a glass floor where light entered the long edge. The projected 
light is almost entirely reflected within the glass except when an object, such as a paw, touches 
it. The light is then scattered and produces an illuminated image of e.g. the paw. The light 
intensity depends on the force of the paw-floor contact and the accumulated light intensity for 
all pixel in a paw print gives an indirect measure of the weight bearing. A video-camera 
mounted underneath the glass floor to film the animal as it crossed the walkway gives a number 
of two-dimensional as well as temporal parameters. In our studies, rats or mice were placed in 
a goal-cage containing all their cage-mates at the exit of the walkway, and was brought one at 
a time to the entrance of the walkway. They were allowed to habituate to the walkway and 
without interference make their own way to the exit in order to find the goal cage and their 
cage-mates. At least two training sessions were performed before the study was started. 
Looking at the films in a pilot study, manual scoring of the weight bearing during locomotion 
in rats was performed using a visual rating scale, based on the prints and the walking pattern 
and adapted from the rating scale described by Coderre and Wall (1987) (Paper II). In the 
following studies, two different methods for automated analysis of the results were used; the 
CatWalk and the PawPrint.  
The CatWalk, developed by Frank Hamers and later purchased by Noldus (Noldus Information 
Technology, The Netherlands), consisted in its first version (Paper I) of an analysing tool 
where the experimenter interactively categorized the points of contact: right/left, fore/hind paw, 
nose, abdomen, tail and artefacts. This process was later automated, but retained the possibility 
to edit the resulting classifications (Paper V, VII and VIII). Parameters used in our CatWalk 
studies include: print area, weight load (mean light intensity), stance phase duration, regularity 
index, walking speed, duty cycle, and weight bearing (Table 2). The PawPrint (developed by 
AstraZeneca, Sweden) was a custom made computer program for rats only (Paper II, IV and 
VI), with an automated analysis of the crossing. The program immediately calculated results 
and displayed a picture of the prints in false colours (one colour for each paw) which allowed 
the experimenter to make a quality check of the results. Editing of the classifications were not 
possible. If results were not acceptable, the rat was allowed to walk again across the walkway 
to give at least three paw placements by each non-arthritic paw. Parameters used in our 
PawPrint studies include weight bearing and regularity index. 
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Table 2. Description of parameters from the CatWalk 
 
PARAMETER PAPER DESCRIPTION CALCULATION 
WEIGHT 
BEARING 
 
Paper II, IV, 
V, VII, VIII 
Calculated force of a paw against the 
glass floor 
Max contact area x Mean intensity 
WEIGHT 
BEARING (%) 
 
 
Paper II, IV, 
V, VI, VII, 
VIII 
Weight bearing of a paw relative to all 
paws 
(Calculated weight bearingpaw/Σ 
calculated weight bearingall paws) x 100 
GUARDING 
INDEX (%) 
 
 
Paper II, IV, 
V, VII 
Difference in percent weight bearing 
between the non-injured hind paw and 
the injured hind paw 
Weight bearing (%)non-injured paw – 
weight bearing (%)injured paw 
PRINT AREA 
 
 
Paper I The entire surface area of the complete 
print 
 
LIGHT 
INTENSITY 
 
 
 
Paper I The average max light intensity 
(arbitrary unit 0-255) of all pixel in a 
print area, which is an indirect measure 
of weight load put on the glass floor 
 
DURATION OF 
STANCE PHASE 
 
Paper I, VII Duration of contact of a paw with the 
glass floor 
 
DUTY CYCLE 
 
 
 
Paper V, VII, 
VIII 
The duration of the stance phase as a 
percentage of the entire step cycle 
(stance + swing)  
[Stance time / (Stance time + Swing 
time)] x 100 
STRIDE LENGTH 
 
 
Paper VIII The distance between successive 
placements of the same paw 
 
SWING SPEED 
 
 
Paper VIII The speed of the paw as it is moved from 
one placement to the next 
 
WALKING 
SPEED 
 
Paper V, VII Average speed of the selected steps in 
the walkway crossing 
 
REGULARITY 
INDEX (%) 
Paper I, II, V, 
VII, VIII 
The number of normal step sequence 
patterns (NSSP) relative to the total 
number of paw placements (PP) 
[(NSSP x 4) / PP] x 100 
 
3.3.2 Stationary weight bearing 
Scoring of the stationary weight bearing in rats in an acrylic test box filmed from underneath 
was performed using an extended version of the visual rating scale, previously described by 
Coderre and Wall (1987) (Paper II).  
Mice were tested for stationary weight bearing using the Advanced Dynamic Weight Bearing 
(DWB; Bioseb, France). This device consists of an 11cm x 11cm floor, with transparent walls 
and a removable top equipped with a camera. The floor is covered by a pressure mapping sensor 
mat (TecScan) containing 1,936 SenselsTM which indirectly register the weight of each paw. 
The mouse was allowed to move freely within the enclosure for five minutes, but measurements 
were only obtained when it was immobile, and the total time giving results ranged between 1.5 
and 3 minutes. Weight bearing in grams was given for each paw, and the relative weight bearing 
in percent of the total body weight calculated. In addition, the duration of floor contact in 
percent of the entire measurement time is given (paper VII and VIII). 
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3.3.3 Static weight bearing 
Using the Incapacitance tester (Linton Instrumentation, UK) the static weight bearing of the 
two hind paws was assessed in rats. The animals were placed in restrainers with the front paws 
on a ramp and their hind paws resting on two separate scales which measured the load of each 
paw. The average of five consecutive recordings, each lasting three seconds, were calculated, 
and weight bearing is shown as percent of both hind paws (Paper V and VI). 
3.3.4 Mechanical sensitivity 
Optihair von Frey filaments (MARSTOCK nervtest, Germany) with logarithmically 
incremental stiffness were used to assess mechanical sensitivity in both rats and mice (Paper 
V and VIII). The animals were placed in individual enclosures on a wire mesh floor. Rats were 
habituated to the observation boxes for 10 minutes before testing, while mice needed 
habituation for at least 30-40 minutes. Filaments were applied perpendicular to the plantar 
surface from underneath the grid floor until slight buckling of the filament. The 50% 
withdrawal threshold was calculated using the up/down method (Chaplan et al., 1994, as 
adapted from Dixon 1980); in the event of a paw withdrawal a positive response was noted, 
and a filament with a lower bending force was subsequently applied; in the case of no paw 
withdrawal a filament with a higher bending force was applied.  
3.3.5 Cold sensitivity 
Acetone was applied from underneath to the plantar surface of the hind paw to assess cold 
sensitivity in mice (Paper VIII). After habituation in enclosures on a wire mesh floor, 
approximately 10 µl of acetone was applied and the time spent reacting (e.g. licking, biting or 
shaking) was measured over 60 seconds. This procedure was repeated three times and the mean 
value was calculated. 
3.3.6 Thermal sensitivity 
Using the Hargreaves´ apparatus, mice were tested for latency to withdrawal from a beam of 
radiant heat stimulus directed from underneath onto the plantar surface of the hind paw (Paper 
VIII). Before testing, the mice were habituated in Plexiglass enclosures on a glass surface. This 
procedure was repeated three times for each hind paw, and the mean value was calculated. 
3.3.7 The formalin test 
The formalin test in mice consists of recording the behaviour subsequent to dorsal 
subcutaneous injection into one hind paw of 10 µl formalin 5% in physiological saline (Paper 
VIII). The injection was performed under isoflurane anaesthesia, and the animals were directly 
afterwards put into Perspex enclosures (13 cm x 13 cm) resting on a pane of Lexan 
(polycarbonate), and filmed from the front with a mirror fitted at an angle below the box to 
make it possible to observe in detail what the animal was doing also from underneath. The 
amount and time spent flinching or licking/biting the injected paw was recorded in 12 blocks 
of 5 minutes for a total of one hour. 
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3.4 COLLECTION OF FLUIDS AND TISSUES 
3.4.1 Blood 
3.4.1.1 Blood collected for exposure analysis in pharmacological effect studies 
Blood was collected via heart puncture into test tubes containing EDTA at termination of 
testing from anaesthetized rats included in the behavioural effect studies and centrifuged to get 
plasma in Paper II and IV. To get information of the plasma exposure also at the time-points 
of behavioural testing, blood was obtained from the tail vein from three satellite animals per 
treatment group. Samples were kept on ice until centrifugation at 4°C and supernatants from 
all samples were stored at -80°C until analysis. Analysis of drug exposure was performed using 
a bioanalytical method that was developed for each drug to determine concentrations in the low 
nanomolar range in plasma samples by reversed-phase liquid chromatography and electrospray 
tandem mass spectrometry.   
3.4.1.2 Blood collected for analysis of inflammatory biomarkers 
Blood was collected via heart puncture and divided into two tubes; one without additives to 
yield serum, and another containing EDTA to yield plasma (Paper III). To get serum, the 
blood was kept in room temperature until clotting (approximately 30 minutes) and then 
centrifuged at 4°C and supernatants from all samples were stored at -80°C until analysis. 
3.4.2 Synovial fluid 
Synovial fluid was collected immediately following sacrifice of the rat by intra-cardiac 
injection of pentobarbital (Paper III, IV and VI). The skin was cut transversally above the 
ankle or the knee joint and the ligament above the joint punctured by a scalpel. The synovial 
fluid was collected by rinsing the joint cavity four subsequent times by a pipette containing 25 
µl 0.05M EDTA (Sigma, pH 7.5). Samples were kept on ice until centrifugation at 4°C and 
supernatants from all samples were stored at -80°C until biomarker analysis. 
3.4.3 Hind leg joints 
Ankle or knee joints were taken from rats in Paper VI, and from mice in Paper VII. Joints 
were taken immediately after euthanasia, skin and soft tissues carefully removed and the 
diaphyses carefully opened proximal and distal of the joint to ensure rapid internal fixation. 
The joints were then fixated in 4% phosphate buffered paraformaldehyde (Histolab Products 
AB) for at least 24 hours. Decalcification of the mineralized tissue was done in EDTA (0.1 
mol/l, pH 7.4; Sigma-Aldrich) for at least two weeks before dehydration and embedding in 
paraffin. 
3.4.4 Nervous tissue and skin 
The plantar skin from hind paws, the sciatic nerves and the L5 dorsal root ganglion were 
harvested in Paper VIII, from mice deeply anesthetized with isoflurane and transfused 
transcardially with phosphate-buffered saline (PBS) followed by 4% paraformaldehyde. The 
tissue was post-fixed and cryoprotected in 20% sucrose in PBS until embedding in paraffin. 
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3.5 BIOCHEMICAL BIOMARKER ANALYSIS  
3.5.1 Colometric assay 
In Paper III and VI, L(+)-Lactate levels were assessed in synovial fluid from rats. Samples 
were diluted up to 1:32 with the provided kit buffer before transferral to a 96-well microplate. 
After mixing with an equal volume of the reaction mix provided by the vendor, the samples 
were incubated for 30 minutes at room temperature before the microplate was read at 570 nm 
on a Spectramax 340 (Molecular Devices). By extending the standard curve and converting the 
concentrations to millimoles per litre, the colorimetric assay (Biovision) was slightly modified, 
and the lower limit of quantification (LOQ) was 0.02 mmol/l.  
3.5.2 Immunoassay 
3.5.2.1 NGF 
Levels of rat NGF were assessed in synovial fluid in Paper IV. This immunoassay was 
developed using electro-chemiluminescence (ECL) technique, where plates were coated with 
rat beta-NGF antibody, then blocked with 3% bovine serum albumin for 30 minutes before 
washing. Synovial fluid samples were diluted 1:4 in assay diluents and added to the plates to 
incubate for 2 hours. Recombinant rat beta-NGF was used as a calibrator. After washing, rat 
Beta-NGF biotinylated antibody provided with MSD Sulfo TAG (Meso Scale Discovery) was 
dispensed to all wells and the plates were incubated to an additional 1.5 hours. Once again the 
plates were washed, followed by adding read buffer to the wells and subsequent analysis on 
the SECTOR Imager (SI6000, Meso Scale Discovery). The LOQ was 9.77 pg/ml. 
3.5.2.2 Cytokines and chemokines 
Levels of MCP-1, MIP-3α, KC/GRO and IL-6 were assessed in synovial fluid, serum and 
EDTA plasma from rats in Paper III, and in synovial fluid in Paper VI. Plasma and serum 
samples were diluted 1:2, and synovial fluid was diluted 1:4 in assay diluents and added to the 
plates. Custom-made immunoassay kits (Meso Scale Discovery), tested and validated for all 
matrices following the manufacturer´s instructions were used. Concentrations of IL-1ß and 
TNF, assessed in synovial fluid, serum and EDTA plasma from rats in Paper III, were assessed 
using commercially available multiplex immunoassay kits. The LOQ, corrected for dilutions, 
were 624 pg/ml for MCP-1, 39 pg/ml for MIP-3α, KC/GRO, Il-1ß and TNF, and 79 pg/ml for 
IL-6. 
3.6 IMMUNOHISTOCHEMISTRY 
 
Joints imbedded in paraffin were cut in 4-6 µm serial sections, mounted on glass slides and 
stained with Safranin-O (Paper VI) to detect loss of proteoglycan in the rat cartilage 
extracellular matrix, done under light microscopic analysis using a Zeiss Axioplan 2 
microscope, or Sag-O-Fast (Paper VII) followed by a semi-quantitative scoring according to 
Osteoarthritis Research Society International (OARSI) histological scoring for mice. 
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Nervous tissue cut in 12 µm serial sections were mounted on glass slides and rehydrated with 
PBS, permeabilized with 0.2 Triton X in PBS, and incubated with 5% normal goat or donkey 
serum in 0.2% Triton X/PBS to block non-specific binding (Paper VIII). The sections were 
subsequently incubated overnight at 4° with different primary antibodies: 
 
Primary antibody Vendor Catalog number Dilution 
Rat anti-TrkA R&D Systems AF1056 1:100 
Rabbit anti-PGP 9.5 Abcam Ab37188 1:1000 
Rabbit ant-CGRP Sigma C8198 1:2000 
Mouse anti-Tuj-1 Promega G7121 1:2000 
 
To visualize the immunoreactivity, the secondary antibodies were conjugated to Alexa 488 
(1:300; Life Technologies), Alexa 555 (1:300; Life Technologies), Cy2 (1:300; Jackson 
Laboratory) or Cy3 (1:600; Jackson Laboratory). An inverted fluorescence microscope was 
used to acquire the images. 
The number of fibres/µm3 and the fibre length/µm3 was assessed in glabrous skin using the 
Fibre Nerve Counting Rules (33, 34) and quantification of sciatic nerve fibres labelled with the 
antibodies described above was carried out using a custom script; 20 lines at even intervals 
throughout the region of interest were drawn perpendicular to the direction of axons and the 
pixel intensities along each line were plotted. The intensity matrices were then processed 
through a peak-detection algorithm to detect the labelled nerve fibres represented as positive 
intensity peaks on individual line plottings. The proportion of CGRP positive fibres in Tuj1 
positive nerve fibres was analysed in four to five sections per animal (with a minimum of 30 
μm apart) and the average value for each animal was calculated. For quantifying the proportion 
of TrkA positive neurons in L5 DRG, the number of TrkA positive neurons was counted and 
divided by the number of PGP9.5 (pan-neuronal marker) positive neurons. Four to five sections 
per animal (with a minimum of 30 μm apart) were analysed and the average value for each 
animal was calculated. 
3.7 ASSESSMENT OF INFLAMMATION 
 
The diameters of ankle or knee respectively were assessed in Paper III, VI, VII and VIII, 
taking the mean of 3 measurements from a three-button digital calliper (Limit, Alingsås, 
Sweden).  
3.8 STATISTICAL ANALYSIS 
 
Two-way analysis of variance (ANOVA) was used for behavioural studies where changes over 
time were compared. Duncan´s test was used as post-hoc test in Paper I, and Bonferroni´s 
multiple comparison test in Paper II, IV, VI, VII and VIII. In Paper V, the non-parametric 
Mann-Whitney test for each time point was used instead, as not all time points included all rats 
and the variances were not equally distributed.  
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When comparison was made between three or more groups, one-way ANOVA followed by 
Dunnett´s multiple comparison was used in Paper II and VII. When analysing the effects of 
treatment in the carrageenan-induced monoarthritis in Paper IV, one-way ANOVA was 
followed by Bonferroni´s t-test versus the vehicle group, and levels of NGF in synovial fluid 
were analysed by the non-parametric Kruskall-Wallis one-way ANOVA followed by Student-
Newman-Keuls method. In Paper V the Kruskall-Wallis test was used followed by Dunn´s 
multiple comparison test. Levels of L(+)-Lactate in Paper VI were analysed using Kruskall-
Wallis test with Mann-Whitney´s post hoc test. 
 
Differences between two groups were analysed by student´s t-test (Paper VII and VIII). 
However, data in Paper III from the rat plasma and serum groups were log-transformed before 
comparison with the t-test, whereas comparison between cytokine levels in human patients and 
healthy controls was done using the Mann-Whitney U-test. 
 
In Paper II, the non-parametric Kendall rank correlation coefficient test was used to compare 
visual scoring of static versus dynamic paw pressure in rats. Pearson´s correlation coefficient 
with the corresponding P-value was used in Paper III and VII. 
 
Data in Paper I, II and VIII are presented as the mean ± standard error of the mean (SEM). 
In Paper IV, the behavioural data are presented as the mean ± SEM, and the levels of NGF in 
synovial fluid are presented as the mean ± 95% confidence interval (CI). Data in Paper III, V, 
VI and VII are presented as the mean ± 95% CI. Results from analysis of biochemical mediator 
levels in Paper VI are presented as individual levels and medians. Statistical significance is 
shown as *P < .05, **P < .01, ***P < .001. Software for statistical tests were SigmaPlot 11.0 
(Paper I, II and IV), GraphPad Prism 6.00, 6.03 or 7 (Paper III, V, VI, VII and VIII), and 
SAS/STAT 9.3 (Paper III). 
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4 RESULTS 
4.1 GAIT AND WEIGHT BEARING AS OUTCOME MEASURE OF 
SPONTANEOUS PAIN IN ANIMAL MODELS OF ARTHRITIS 
4.1.1 Carrageenan, CFA- and MIA-induced monoarthritis in rats 
Paper I, II, IV, V, VI 
The effects of a short-lasting inflammatory model – carrageenan-induced monoarthritis – was 
tested to establish its suitability for further studies. The effects on weight bearing while standing 
(static) was tested using the Incapacitance tester, where naïve rats put close to 50% of the 
weight on each hind paw. Rats with carrageenan intra-articular ankle joint injection (7.5 mg/ml; 
375 µg in 50 µl) reduced the weight bearing of the injected paw to values between 31% and 
33%, assessed at 3, 5 and 24 hours after injection (Paper II, Fig 10).  
Using the CatWalk setup, the effects of carrageenan injected into the ankle joint on gait and 
weight bearing during locomotion was assessed. Compared to saline injected animals, the 
monoarthritic rats showed significantly reduced print area, mean weight load (light intensity) 
and duration of stance for the injected paw at all times tested, and loss of inter-limb 
coordination (Paper I, Fig 3).  
As the CatWalk was not commercially available at the time, AstraZeneca built a similar 
equipment in-house, based on the same principles, and named it PawPrint. The analysis 
algorithms in the PawPrint allowed for immediate automated analysis, with results shown as a 
picture of the prints in false colours for easy identification (Figure 3), and thus allowed for a 
quality check of the results (Paper II, Fig 1).  
 
Figure 3. Picture of prints from a naïve rat and a rat with monoarthritis from the PawPrint analysis.  
Prints from the left side are coloured red, and prints from the right side blue. Light colours show front 
paws, while dark colours show hind paws.  
The parameters included print area and light intensity from all prints. Using accumulated light 
intensity from the number of pixel in a print area we calculated weight bearing. The four 
median values from prints of the four paws were chosen from a walkway crossing, and the 
relative contribution for each paw was calculated as per cent of the sum of weight bearing 
values for all paws. The difference in percent weight bearing between the two hind paws was 
calculated to show the shift in weight bearing from the inflamed hind paw to the non-inflamed 
hind paw, and this new parameter was named guarding index. Using the PawPrint setup a range 
of seven concentrations of carrageenan injected into one hind paw ankle joint was tested. The 
results showed that the reduction in weight bearing of the injected hind paw was compensated 
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by increased weight bearing of the front paw on the same side as the injected paw, and by the 
contralateral hind paw (Paper II, Fig 6). The guarding index, showing values close to zero in 
naïve or saline-injected rats, increased significantly and concentration-dependently already 
from the low amount of 0.024 µg at 5 hours after injection, and lasted for up to 48 hours after 
the high amount of 1500 µg (Paper II, Fig 7). Regularity index, close to 100% in naïve or 
saline-injected rats, demonstrate that those animals use all four paws in a coordinated fashion 
during locomotion. Carrageenan concentrations above 1.9 mg/ml (0.095 µg) significantly 
reduced the regularity index, but these effects were normalized at 24 hours after injection. 
Subsequently FCA, in concentrations between 0.12 to 8.0 mg/ml (0.006 to 400 µg in 50 µl), 
was used to induce ankle joint inflammation and effects measured with the PawPrint setup. 
Similar effects regarding the four paw’s weight bearing as after injection of carrageenan were 
found (Paper II, Fig 4), but the increase of guarding index was significant for all concentrations 
(even for Freund’s incomplete adjuvant) and lasted for more than 10 days for the high 
concentration (Paper II, Fig 5). Regularity index was decreased significantly for all 
concentrations at some time point, but again lasted for a shorter time period than did effects on 
weight bearing. 
Next, MIA in a concentration (2 mg in 50 µl; 2000 µg) that had previously been shown to 
induce weight bearing deficits (Combe et al., 2004) was injected into the ankle joint and tested 
for effects on weight bearing during locomotion up to 28 days after injection. Surprisingly, a 
reduction in weight bearing of the injected paw, compensated by an increase in the contralateral 
hind paw, was only seen at one day after induction (Paper VI, Fig 1A). As published results 
are all based on the effects of MIA intra-articular injection into the knee joint, this was then 
tested and showed significant effects on weight bearing during locomotion, but which started 
only at three weeks after induction. In contrast, static weight bearing was significantly reduced 
from day 1, not on day 7, but lasted for the rest of the 28 days test period (Paper VI, Fig 2B). 
To further elucidate the differences between monoarthritis induced in the ankle joint compared 
to the knee joint, both carrageenan (375 µg), FCA (50 µg) and MIA (2000 µg) groups with 
knee joint injection were included in the studies using ankle joint injection. The effects of the 
joint inflammation on weight bearing during locomotion were more pronounced when injecting 
into the ankle joint for all agents (Figure 4), and the responses after intra-articular injection of 
carrageenan and FCA were stronger. Only MIA-induced knee monoarthritis in rats developed 
a second phase (Paper VI, Fig 2A), at the time when cartilage breakdown has been reported 
(Guinkamp et al., 1997; SBU, 2006), and no tendency of a second phase was found after one 
single joint injection of carrageenan or FCA. 
To compare the usage of the injected paw when standing to that when walking, rats with 
monoarthritis induced by injection of Freund´s complete adjuvant were filmed from 
underneath, both in a box (length 30cm, width 20cm, and height 18cm) and in a walkway 
(length 1m, width 10cm, open top), and later scored manually for guarding/paw pressure with 
the rating scale described by Coderre and Wall 1987. Results showed that guarding scores were 
always higher as the rats walked compared to when they were standing still (Paper II, Fig 3). 
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Figure 4. Injection site of carrageenan (7.5 mg/ml, upper panel), FCA (1.0 ml/ml, middle panel) and 
MIA (2 mg, lower panel) plays a role for magnitude of response on guarding index assessed in the 
PawPrint. Bonferroni´s test subsequent to 2-way ANOVA: *P < .05, **P < .01, ***P < .001 compared 
to the control group at the same time point. Data shown as mean ± SEM, n = 10 per group. (Adapted 
from Paper II, Figs 8 and 9) 
4.1.2 Pro-inflammatory biomarkers in synovial fluid and blood after CFA- and 
MIA-induced monoarthritis in rat 
Paper III, IV, VI 
To more closely study also the levels of inflammatory factors in the joint, and compare to levels 
in the blood, we performed an additional study. Here we used FCA (50 µg) and MIA (2000 
µg) to induce monoarthritis, and plasma, serum and synovial fluid was collected from rats at 
several time-points and analysed for contents of IL-1β, IL-6, KC/GRO, MCP-1, MIP-3α, TNF 
and the indicator of a successful induction of inflammation; L(+)-lactate (Finn and Oerther, 
2010). All markers showed elevated levels in synovial fluid from monoarthritic rats compared 
to control groups, although with considerably lower magnitude in the MIA injected rats, where 
indications of a biphasic pattern appeared (Paper III, Figs 1 and 2). Levels of KC/GRO and 
MIP-3α in serum from the FCA model, and IL-6 in serum from the MIA model followed the 
pattern of levels found in the synovial fluid.  
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To compare some of the same inflammatory factors in ankle versus knee intra-articular 
injection of MIA (2000 µg), synovial fluid was collected at termination of the 28 day 
behavioural MIA study. Results confirmed the disparate injection site profiles; thus knee 
injection caused elevated levels of MCP-1, MIP-3α, KC/GRO and IL-6 whereas ankle injection 
resulted in inflammatory factors at levels similar to those in naïve rats at 28 days after injection 
(Paper VI, Fig 4). Additionally, joint pathology showed similar differences; only injection of 
MIA into the knee joint caused severe cartilage erosions, exposure of subchondral bone and 
osteophyte formation, while ankle joint injection caused very mild changes in a few rats (Paper 
VI, Figs 5 and 6). 
4.1.3 CFA-induced monoarthritis in mice 
Paper VII, VIII 
At Karolinska Institutet, the focus for me has shifted to using mice as test species.  
Tests with monoarthritic mice assessing stationary weight bearing on the DWB showed that 
this setup produced data revealing a robust separation between monoarthritic (CFA; 10 and 
100 µg) compared to control animals. Naïve mice exerted significantly more weight on hind 
paws (≈80%) than on front paws (≈20%), and hind paws stayed in contact with the floor for 
longer. Mice with CFA injected into the ankle joint of one hind paw showed reduced stationary 
weight bearing of the injected paw, outlasting the 2-week testing period. A corresponding 
increase of weight bearing was seen for the front paw on the injected side, and to some degree 
also for the non-injected hind paw. Similarly, the duration of floor contact was reduced for the 
injected hind paw and increased for the front paw on the injected side (Paper VII, Fig 2).    
Using the CatWalk setup to test mice induced with CFA monoarthritis (10 and 100 µg) for 
changes in gait and weight bearing during locomotion, similar features as those found in rats 
were found; the weight bearing of the injected paw was drastically reduced, while the other 
paws compensated for the loss of weight bearing. However mice compensated by putting more 
weight not only on the contralateral hind paw, but also on the contralateral front paw, in contrast 
to rats that compensate with the contralateral hind paw and ipsilateral front paw. Moreover, the 
high amount CFA (100 µg) caused a prolonged behavioural effect, and no return to normal 
usage of the paws was seen over the two week test period (Figure 5). 
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Figure 5. Guarding index assessed on the CatWalk in mice with injection of FCA (10 and 100 µg) into 
one hind paw ankle joint. Bonferroni´s test subsequent to 2-way ANOVA: *P < .05, **P < .01, ***P < 
.001 compared to the control group at the same time point. Data shown as mean ± SEM, n = 10 per 
group. (Adapted from Paper VII, Fig 3) 
 
In Paper VIII; manuscript, we tested mice with the human wild-type NGF gene, injected with 
CFA (10 mg/ml; 5µl or 10µl into the ankle or knee joint respectively) for effects on stationary 
(DWB) and dynamic (CatWalk) weight bearing. These mice showed similar response to those 
tested for Paper VII; significant reduction of the injected hind leg´s weight bearing (Paper 
VIII, Figs 6 and 7; manuscript). 
4.1.4 Anterior cruciate ligament transection in mice 
Paper VII 
During the eight weeks of testing mice with sham surgery for stationary weight bearing on the 
DWB, this control group resembled previous data; ≈80% weight bearing was on the hind paws 
and ≈20% was on the front paws. The duration of floor contact showed a similar pattern.  
After ACLT surgery, the injured paw exerted less body weight for two weeks and then returned 
to normal. The weight bearing decrease was compensated by a small increase on the non-
injured hind paw and on the front paw on the side of the surgery. However, the small increase 
in weight bearing of the non-injected hind paw remained evident until the end of the study, and 
resulted in a significant increase of the stationary guarding index which correlated with the 
degree of structural changes in the injured joint (Figure 6). The duration of floor contact was 
affected for one week post-surgery only (Paper VII, Fig 1; manuscript). 
 
Figure 6. Guarding index assessed on the DWB in mice with injection of FCA (10 and 100 µg) into 
one hind paw ankle joint (upper panel), and in mice with ACLT in one hind leg knee joint (lower panel). 
Bonferroni´s test subsequent to 2-way ANOVA: *P < .05, **P < .01, ***P < .001 compared to the 
control group at the same time point. Data shown as mean ± SEM, n = 10 per group. (Adapted from 
Paper VII, Figs 1 and 2) 
p re 1 2 3 4 5 6 7 1 0 1 4  d a y s
0
2 0
4 0
6 0
T im e  a fte r  in je c tio n  o f C F A
G
u
a
r
d
in
g
 i
n
d
e
x
 (
%
)
C F A  2 .0  m g /m l
C o n tro l
C F A  1 0  m g /m l
* * *
* * *
0
2 0
4 0
6 0
T im e  a fte r  A C L T  s u rg e ry
G
u
a
r
d
in
g
 i
n
d
e
x
 (
%
)
A C L
S h a m
* * *
* * *
* * *
* * *
* * **
p r e 3 d 1 2 3 4 5 6 7 8  w e e k s
 
 32 
4.2 ARTHRITIS-INDUCED CHANGES IN GAIT AND WEIGHT BEARING ARE 
NORMALIZED BY CONVENTIONAL PAIN RELIEVING DRUGS 
Paper I, II, IV, V 
When assessed on the PawPrint, rats with monoarthritis induced by carrageenan or CFA 
reached guarding index levels of about 30%, from levels around 0% before induction and in 
control rats; naïve or injected by saline into the ankle joint.  
 
In rats with carrageenan induced monoarthritis the drugs were given before testing at a time-
point which produced the highest plasma concentration at testing, as established by the 
DMPK department at AstraZeneca. Single administration of the tested compounds produced 
dose-related reductions in the response to carrageenan as measured by the guarding index 
(Figure 7). Significant effects were seen at doses of 10 (naproxen), 100 (ibuprofen), 1 
(diclofenac), 3 (oxycodone) and 2000 (paracetamol) µmol/kg, corresponding to 2.3 
(naproxen), 23 (ibuprofen), 0.30 (diclofenac), 1.1 (oxycodone) and 300 (paracetamol) mg/kg. 
All compounds produced dose related total plasma exposures (Paper II, Table 2).  
 
Figure 7. Guarding index assessed on the PawPrint in rats with carrageenan monoarthritis (7.5 mg/ml) 
of one hind paw ankle joint. Dunnett´s test subsequent to 1-way ANOVA: *P < .05, **P < .01, ***P < 
.001 compared to the control group. Data shown as mean ± SEM, n = 8-10 per group. (Adapted from 
Paper II, Table 2) 
 
Administration of the non-selective COX inhibitors naproxen and ibuprofen (Paper IV, Fig. 
6A–D) also attenuated the increase in guarding index induced by FCA ankle injection. The 
highest doses of naproxen (90 mmol/kg) and ibuprofen (300 mmol/ kg) normalized guarding 
index on day 3 of treatment compared to the respective vehicle treated groups. The two COX-
2-selective inhibitors valdecoxib and rofecoxib (Paper IV, Fig. 7A–D) showed similar 
normalising effects on guarding index (Figure 8). The effects were statistically significant at 3 
days after treatment start compared to vehicle treated rats. But the degree of normalization is 
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not as high as that seen in the carrageenan monoarthritis. The total plasma concentrations 
remained stable during the test period for all COX inhibitors (Paper IV, Table1). 
 
Figure 8. Guarding index after 3 days of daily treatment, assessed on the PawPrint in rats with FCA 
monoarthritis (50 µg) of one hind paw ankle joint. Bonferroni´s test subsequent to 2-way ANOVA was 
performed on the total test time: *P < .05, **P < .01, ***P < .001 compared to the control group. Data 
shown as mean ± SEM, n = 11-12 per group. (Adapted from Paper IV, Figs 6 and 7) 
 
4.3 NGF BLOCKAGE AND TRKA ANTAGONISTS REVERSE ARTHRITIS-
INDUCED CHANGES IN WEIGHT BEARING AND GAIT, BUT A TRPV1 
ANTAGONIST FAILED TO DO SO 
Paper IV, VII 
First we assessed the release of NGF in synovial fluid of the joint subsequent to induction of 
inflammation with FCA (50 µg), and compared levels to those in the synovial fluid from saline 
injected rats. NGF levels were significantly elevated in synovial fluid from intra-articular ankle 
joint FCA injected rats, reaching maximum at days one and two, but were still significantly 
increased on days five and ten after the joint injection (Paper IV, Fig 1).  
To investigate whether blockade of NGF or its receptor TrkA could normalize weight bearing 
during voluntary locomotion after induction of joint inflammation, we tested two pan-Trk 
inhibitors - AZ6623 and AZ7092 – in rats after ankle joint injection of carrageenan (375 µg), 
using the PawPrint setup. Both showed normalization of the guarding index in a dose-related 
manner, but couldn´t completely restore the weight bearing to that of naïve rats (Figure 9). 
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Figure 9. Effects of the pan-Trk antagonists AZ6623 and AZ7062 on carrageenan-induced changes in 
guarding index are shown in (A) and (B) respectively. AZ6623 (n = 8/group) and AZ7092 (n = 10-
12/group) were given as a single administration orally, 1 h after ankle joint injection of carrageenan, 
and testing was performed 2 h later. Data shown as mean ± SEM, and analysed by 1-way ANOVA 
followed by Bonferroni´s t-test. *P < .05, **P < .01, ***P < .001 compared to the respective 
carrageenan injected vehicle group. (From Paper IV, Fig 4) 
 
Next the pan-Trk inhibitors AZ6623 and AZ7092, and the anti-NGF antibody MEDI-578 were 
tested in the PawPrint setup for effects on FCA-induced guarding index during voluntary 
locomotion (Figure 10). Here, one of the pan-Trk inhibitors was slightly more efficacious than 
the NGF antibody, but all were more efficacious than the previously tested NSAIDs. Thus, the 
normalization of guarding index compared to vehicle treated rats reached approximately 60 to 
80% (Figs 2 and 3 in paper IV). 
 
Figure 10. Guarding index at 3 days after one single intravenous injection of MEDI-578, assessed on 
the PawPrint in rats with FCA monoarthritis (50 µg) of one hind paw ankle joint. Bonferroni´s test 
subsequent to 2-way ANOVA was performed on the total test time: *P < .05, **P < .01, ***P < .001 
compared to the control group. Data shown as mean ± SEM, n = 11-12 per group. (Adapted from Paper 
IV, Fig 2) 
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In contrast, when testing a TRPV1 inhibitor at a high dose, no effect was observed (Figure 11). 
  
Figure 11. Guarding index before and at 3 days after twice daily oral treatment of AZD1386, assessed 
on the PawPrint in rats with FCA monoarthritis (50 µg) of one hind paw ankle joint. 2-way ANOVA 
was performed. Data shown as mean ± SEM, n = 25 per group. (Adapted from Paper IV, Fig 5A) 
 
In mice, significant effects on stationary guarding index (DWB) was achieved one day after 
MEDI578 injection for the two lower doses (0.3 mg/kg and 1.0 mg/kg) and at three days for 
all doses. When the same mice were tested in the CatWalkTM, a significant reduction of 
guarding index during locomotion was attained only with the high dose (3.0 mg/kg) three days 
after injection, and the dose relationship was weak (Figure 12).  
 
Figure 12. Guarding index before and after one single subcutaneous injection of MEDI-578, assessed 
on the DWB and CatWalk in mice with CFA monoarthritis (10 µg) of one hind paw ankle joint. The 
guarding index of naïve mice before CFA injection is referred to as “no pain”, while “max pain” refers 
to results at one day after CFA injection, before drug treatment. Each individual mouse´s difference 
between measurements at “max pain” and the corresponding measurement at each time point after 
treatment start was used for subsequent analysis. 1-way ANOVA followed by Dunnett´s test versus 
isotype control mice was performed. Data shown as mean ± 95% CI, n = 11 per group. (From Paper 
VII, Fig 4 A and B) 
 
Willingness to place the injured paw on the floor was increased already one day after treatment 
by some doses, and all doses reached significant effects three days after injection, both when 
assessed when the mice were stationary and during locomotion (Paper VII, Figs. 4 C and D).  
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All data from the drug effect studies with mice were pooled and results for each individual 
mouse from the DWB versus results from the CatWalkTM were plotted. Stationary guarding 
index (DWB) and guarding index during locomotion (CatWalkTM) correlated strongly, as did 
duration of floor contact versus duty cycle (Paper VII, Figs 4 E and F; p<0.0001 for both). 
4.4 MICE WITH NON-FUNCTIONAL NGF ARE PROTECTED FROM 
ARTHRITIS-INDUCED CHANGES IN GAIT AND WEIGHT BEARING 
Paper VIII 
We characterized mice with mutations in the gene coding for NGF. Homozygous mice with 
the human NGF (hWT mice) or with the human NGF containing a mutation, replacing the 
arginine 100 by glutamic acid in the NGFß gene (hR100E mice), were tested with respect to 
their response to basic sensory tests and their response to acute and longer lasting models of 
inflammatory pain. In addition, nervous tissue from skin, the sciatic nerve and DRG were 
analysed. No difference was found between the two with respect to development of the 
nociceptive system (Figure 13).  
 
Figure 13. Representative images of PGP9.5(+), NF200(+), CGRP(+) and TrkA(+) nerve fibres in the 
glabrous skin of hWT (left) and hR100E (right) mice. Fibre area and length from the contralateral hind 
paw skin of hWT (white; n = 7) and hR100E (black; n = 7) mice. To compare levels between groups, t-
test was performed. Data presented as mean ± SEM. (From Paper VIII, Fig 2 E and F) 
 
Neither was any difference between hWT and hR100E mice regarding baseline mechanical, 
cold or thermal sensitivity found (Paper VIII, Fig 3), nor in response to acute pain as measured 
with the formalin test (Paper VIII, Fig 4). Further, when testing mechanical and thermal 
hypersensitivity after ankle joint injection of CFA (5 µl of 10 mg/ml), no significant difference 
was seen between the two (Paper VIII, Fig 5 B and C). However, when assessing stationary 
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weight bearing (Incapacitance tester) and gait and weight bearing during locomotion (CatWalk) 
after knee joint injection of CFA in those mice, we did see a significant difference (Figure 14). 
 
 
Figure 14. Stationary (dynamic) weight bearing and weight bearing during locomotion assessed on 
the DWB and CatWalk respectively, before and after intra-articular knee joint injection of  CFA (100 
µg) in hWT and hR100E mice of both genders. 2-way ANOVA followed by Bonferroni´s test versus 
baseline values before CFA injection was performed. Data shown as mean ± SEM. The number of 
animals were: male; hWT n = 7, hR100E n = 7; female; hWT n = 5, hR100E n = 7 per group. (Adapted 
from Paper VIII, Fig 6 C and 7 C)  
 38 
5 DISCUSSION AND CONCLUDING REMARKS 
 
The aim of this thesis has been to evaluate models and methods for joint inflammation and 
injury, in order to find those that reflect the symptoms that bring human patients to seek medical 
help; pain while walking. The work for this thesis spans over many years, with the first studies 
being conducted in 1999 in Utrecht on the CatWalk. The pharmacological focus on NGF and 
TRPV1 stems from direct experience of working in projects aiming to develop pain relieving 
drugs using these molecular targets. It can be argued that it´s common knowledge that 
treatments affecting the NGF pathway works and that our work thus does not bring new insight. 
However, at the time when we first tested the anti-NGF antibody in 2005, knowledge of its 
preclinical or clinical effect on joint pain were not widespread. 
 
Our first aim was to investigate three models in rats where an injection into the joint caused 
pain-like behaviour; carrageenan, CFA and MIA. The two first mainly cause robust 
inflammation, while MIA destroys the cartilage. In mice we also used intra-articular injection 
of CFA, and one surgical model; ACLT. All models showed reduced weight bearing, albeit to 
differing extent, of the injured paw. However weight bearing can be assessed in many different 
ways, and we have tested a number of those.  
First, to measure static weight bearing in the rat models we used the Incapacitance tester, where 
the animals were put onto a test device with each hind paw resting on a scale, giving the weight 
exerted by each paw. As the front paws rested on a ramp, without contributing to the total 
weight, the weight bearing for both hind paws always amounted to 100 percent of the body 
weight. Animals are constrained in a holder and have to be trained to get reliable results. It can 
be challenging to get each hind paw to rest on the right scale, and it´s difficult to ascertain that 
the animals are balanced in the middle without their body leaning on the walls. Even so, it 
quickly gives values of weight bearing. In a previously published alternative method, rats were 
put in a box with a flat floor containing force-plates where the two hind paws are placed to give 
the percentage of weight bearing for each, again amounting to a total of 100% for the hind paws 
(Schött et al., 1994).  
Second, the DWB device was used to assess stationary weight bearing in the mouse models we 
tested, to get results from all paws. Here, the animals could move freely and no training was 
necessary. The floor was equipped with a sensor mat where the weight of each paw was 
registered indirectly at periods of immobility, but analysis became very time consuming when 
the necessary validation of the signals from the sensor mat was compared to the videotape 
simultaneously recorded from above. 
The third approach, assessing weight bearing and gait during locomotion, has been the one 
mostly used for our studies. Apart from only getting information on hind paw weight bearing, 
both front paws are also measured. This gives added knowledge on how animals choose to 
compensate for the reduced weight put on an inflamed or injured hind leg. One or two training 
sessions are needed, but after that it takes only a few seconds for an animal to cross the 
walkway, and the quick validation of the automated analysis rapidly gives the final results. This 
approach also gave many other parameters pertaining to gait, such as the relative time spent 
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putting weight on the floor by each paw, the interlimb coordination, i.e. the regularity of the 
four paw´s placement on the floor while walking, and distance between the paw placements. 
Furthermore, we tested an approach where mice were forced to walk within a restrained area 
on a transparent floor (TreadScan from CleverSys); a belt that moved and forced the mice 
forward to avoid getting pushed from behind or even get squeezed between the bumper at the 
end of the walkway and the floor (not reported). Mice induced with CFA monoarthritis became 
very stressed by the setup and many refused to move. The basis for calculating stance pressure 
(≈ weight bearing) was the colour of the plantar side of the paw, which is calibrated for each 
strain of mice. The assumption that the skin colour is changed as it’s placed on the floor and 
small vessels get occluded does not seem to hold true. 
  
All three ways of getting data that we decided to continue with; static, stationary and during 
locomotion, show that joint inflammation alters weight bearing. For the stationary weight 
bearing and that during locomotion we introduced a new calculated result parameter; the 
guarding index, which shows the shift of body weight from the injured hind leg to the non-
injured leg. Guarding index is the parameter mainly used in the figures of this thesis. The 
models we have used give varying effects, both in terms of magnitude and of duration. Thus, 
the two mainly inflammatory models (carrageenan and CFA) showed the largest difference 
between those with injection and controls, whereas the MIA model showed an intermediate 
difference and the surgical ACLT had difficulties reaching significant difference compared to 
controls. Unfortunately, this is opposite to what would be advantageous when studying OA. 
 
Another aim was to test whether conventional pain relieving drugs could normalize the effects 
on gait and weight bearing in the models we used. The carrageenan model, which is the model 
with shortest duration, provided a large difference in guarding index between animals with 
monoarthritis and controls and is therefore suited for pharmacological tests. NSAIDs were able 
to completely restore weight bearing, reducing the guarding index to levels below that of 
controls, but opioids did not reach a similar efficacy. These drugs also showed effect on gait 
parameters such as fraction of total step duration (duty factor) and regularity index. Thus it 
seems that this model lends itself primarily to testing drugs that inhibit COX enzymes. In 
contrast, the NSAIDs tested in the longer-lasting CFA monoarthritis model were unable to fully 
normalize the weight bearing decrease, reaching only around 40% reduction of the guarding 
index. The smaller differences between the two hind leg´s weight bearing (guarding index) in 
the MIA and the ACLT models made it almost impossible to test pain relieving drugs with the 
number of animals per group conventionally used in those studies. It´s unfortunate that models 
mimicking the structural changes seen in OA don´t give the robust behavioural changes needed 
for pharmacological testing of pain-relieving drugs. Perhaps several models could be used to 
include the different aspects of OA pain, in such a way that the CFA-induced monoarthritis, 
albeit definitely not a model of OA, could represent pain occurring from the inflammatory 
aspect, whereas the MIA model more closely resembles the phase of OA pain when the 
cartilage becomes degraded. These two models cannot, however, be used to understand the 
underlying mechanisms of progression disease. To more closely look at those aspects the 
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surgical and natural occurring models are better suited. It´s a challenge to find a model that 
both mirrors the structural changes in OA, and that makes it possible to test new chemical 
targets for pain treatment. The work on the models in this thesis can be summarized in table 3. 
 
Table 3 Comparison between the models used 
Model Inflammation OA-like 
structural 
changes 
Magnitude of 
weight bearing 
changes 
Affected by 
conventional pain 
drugs 
Carra-
geenan 
 
+++  +++ +++ 
CFA 
 
+++ + +++ ++ 
MIA 
 
+ ++ ++ + 
ACLT 
 
 +++ +  
 
The next aim of this thesis was to explore the role of NGF and the ion channel TRPV1 in 
arthritis-induced spontaneous pain. For this we used pharmacological treatments developed by 
AstraZeneca; one anti-NGF antibody and two small molecule inhibitors of the Trk receptors 
A, B and C. In the carrageenan monoarthritis model the pan-Trk inhibiting compounds showed 
significant effects, but the efficacy was below that of all NSAIDs and opioids tested. However, 
in the CFA-induced monoarthritis the anti NGF antibody and the pan-Trk inhibitors were able 
to normalize the CFA-induced increase of guarding index with 60-80%, thus showing a 
stronger effect than that by NSAIDs in this model. Thus it´s clear that the models engage 
different parts of the immunological system, and that the CFA-induced model recruits other 
pathways than those entirely dependent on COX. 
 
The genetically modified mice given to us by AstraZeneca, where the arginine at R100 was 
replaced by glutamic acid in the NGFß gene, responded normally when testing for baseline 
sensitivity and effects of formalin-induced nociception, and showed normal response to tester-
evoked sensory stimuli after induction of CFA-induced monoarthritis. This was in line with the 
normal development and differentiation of the nociceptive system found in nervous tissue of 
these mice. In contrast, assessment of gait and weight bearing in the NGF R100E mutated mice 
showed a significant lack of pain-like response compared to wild-type mice, pointing to the 
larger susceptibility by this mutation in deep tissues of the joint.  
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Figure 15. The difference in percentage of TrkA positive nerves in bone compared to that 
found in skin. (Reprinted with permission from Mantyh et al., 2011)  
 
One of the possible reasons for this disparity between skin and joint sensitivity could be the 
different expression of the TrkA receptor; only about 30% of the sensory nerves in skin are 
TrkA positive, while more than 80% of the sensory nerves in bone are TrkA positive (Figure 
15; Mantyh et al., 2011; Guedon et al., 2016). The information gained by using gait and 
stationary weight bearing or weight bearing during locomotion would not have been discovered 
with the traditional tester-evoked assessments.
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